Susanne Staer

This author has written 413 articles

VitalHub’s Chart Makes Apple’s Top 80 List of Doctor Apps

VitalHub Corp Logo: Patient information made easyVitalHub Chart has been named to Apple’s list of top 80 apps for doctors, nurses, patients and healthcare professionals in the “EMR and patient monitoring” category.

Here’s a description of the app, which is made by Toronto-based VitalHub Corp., from the Apple list curators:

“VitalHub Chart puts patient data at your fingertips. You can access the information you need any time, anywhere there is WiFi or cellular service. No more waiting for a free desktop, hunting for a workstation on wheels, or carrying printouts on rounds.”

Continue Reading

MI’s Elizabeth Monier-Williams to speak at TedxWaterlooWomen December 1

Elizabeth Monier-Williams, marketing and communications manager
Elizabeth Monier-Williams, marketing and communications manager at MaRS Innovation.

Elizabeth Monier-Williams, MaRS Innovation’s marketing and communications manager, is giving a Tedx talk at the TedxWaterlooWomen event in Waterloo, Ontario, on December 1.

Read the Kitchener-Waterloo Record’s summary story and their curated highlights from the event’s social chatter on Storify.

The event, hosted by the Centre for International Governance Innovation (CIGI), will include a live stream of talks from the second annual TedxWomen conference in Washington, D.C., along with talks by local speakers, including Monier-Williams, for the Waterloo audience.

Continue Reading

Gen Magazine features Dr. Aaron Wheeler’s research in microfluidics

MI_kapplexGEN Magazine (Genetic Engineering and Biotechnology News) featured the microfluidics research of Dr. Aaron Wheeler on November 15, 2012.

Wheeler, Canada Research Chair of Bioanalytical Chemistry and an associate professor at the University of Toronto, has made an invention disclosure to MaRS Innovation; Kapplex is the start-up company created to commercialize his research.

Continue Reading

OICR and MaRS Innovation announce funding to develop Cellax™, a nanotechnology-based cancer drug

CellaxTORONTO, ON (November 13, 2012) — The Ontario Institute for Cancer Research (OICR) and MaRS Innovation (MI) today announced $1.5 million in funding from OICR over three years to further develop Cellax™, a nanoparticle drug that could offer an alternative to chemotherapy with fewer side effects.

“Cellax is promising because it provides a more targeted strategy for treating tumours, killing tumour cells while minimizing the effect on healthy tissue,” said Dr. Rima Al-awar, director, OICR’s Medicinal Chemistry Platform. “OICR is proud to invest in a technology that has such potential to one day improve quality of life for cancer patients.”

Cellax, invented by Dr. Shyh-Dar Li and his research team in OICR’s Medicinal Chemistry Platform group, is a drug-polymer conjugate based on Dr. Li’s proprietary NanoCMC™ technology. These polymers self-assemble into defined nanoparticles and, when injected, selectively accumulate in tumours. Because of this property, the drug is released where it is most needed, increasing therapeutic benefits and reducing the side effects associated with conventional chemotherapy.

Continue Reading

Dr. Raphael Hofstein’s guest column posted on Biotechnology Focus

Raphael Hofstein
Raphael Hofstein, president and CEO of MaRS Innovation.

Biotechnology Focus, a compendium of the Canadian life sciences industry, has published a guest column by MaRS Innovation President & CEO, Raphael Hofstein.

The article examines how to build a strong biotechnology cluster from an academic base in the midst of a global recession.

Here’s an excerpt:

Gone are the days of large-scale, well-funded, in-house departments with resources to liberally support academic and start-up collaborations. Financial pressures and the economic downturn have made it clear that the go-it-alone model is no longer sustainable, and industry players are recognizing that they don’t have a monopoly on research acumen and disruptive ideas. Simultaneously, industry has expressed less interest in investing in early-stage technologies that carry significant risk. They remain receptive to the research emerging from academic enterprise, but need a means of bridging the gap that technologies face as they move from the bench to the market.

Continue Reading

Stem Cell Therapeutics, UHN and MaRS Innovation Announce Novel, Clinical-Stage, Cancer Stem Cell Program Agreement

Stem Cell Therapeutics Corp. logo
Stem Cell Therapeutics Corp.

Stem Cell Therapeutics Corp. (TSX VENTURE:SSS), a life sciences company developing stem cell-related technologies, today announced the signing of an agreement with University Health Network (UHN), through its commercialization agent MaRS Innovation (MI), both of Toronto.

The agreement provides Stem Cell Therapeutics (“SCT”) with an option to an exclusive world-wide license to an innovative cancer stem cell program.

This agreement produced a license for a UHN technology on April 17, 2013.

Continue Reading

Yonge Street Media covers Bedside Clinical Systems’ launch

Yonge Street Media, a weekly online magazine that covers talent, innovation, diversity and quality of life stories in the Toronto region, covered Bedside Clinical Systems’ (BCS) launch in their Innovation section on Wednesday, November 7, 2012.

BCS is a MaRS Innovation spin-off company created to commercialize decision-support research emerging from The Hospital for Sick Children (SickKids).

Continue Reading

Quick Links

Contact Us

Schwartz Reisman Innovation Campus, West Tower
108 College Street, Suite 530
Toronto, ON M5G 0C6
info@tiap.ca

© CopyrightTIAP 2024 - All Rights Reserved | Site Map | CASL Policy | Privacy Policy | AODA Compliance
Twitter Linkedin
Back To Top